Compare MYD & VNDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MYD | VNDA |
|---|---|---|
| Founded | 1991 | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Bankers/Brokers/Service | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 479.7M | 474.0M |
| IPO Year | N/A | 2006 |
| Metric | MYD | VNDA |
|---|---|---|
| Price | $10.66 | $7.58 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $13.63 |
| AVG Volume (30 Days) | 253.1K | ★ 1.1M |
| Earning Date | 01-01-0001 | 02-11-2026 |
| Dividend Yield | ★ 4.55% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $212,074,000.00 |
| Revenue This Year | N/A | $12.01 |
| Revenue Next Year | N/A | $24.28 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 11.12 |
| 52 Week Low | $8.76 | $3.81 |
| 52 Week High | $11.30 | $9.60 |
| Indicator | MYD | VNDA |
|---|---|---|
| Relative Strength Index (RSI) | 55.48 | 50.35 |
| Support Level | $10.44 | $7.22 |
| Resistance Level | $10.78 | $8.30 |
| Average True Range (ATR) | 0.11 | 0.42 |
| MACD | 0.01 | -0.10 |
| Stochastic Oscillator | 61.54 | 33.51 |
Blackrock Muniyield Fund Inc is a non-diversified, closed-end management investment company. Its investment objective is to provide shareholders with as high a level of current income exempt from U.S. federal income taxes. The fund invests a majority of its assets in municipal bonds exempt from U.S. federal income taxes (except that the interest may be subject to the U.S. federal alternative minimum tax). These bonds are predominantly long-term (with a maturity of more than ten years at the time of investment), and rated as investment grade, or deemed to be of comparable quality by the investment adviser at the time of investment. The fund can also invest directly in such securities or synthetically through the use of derivatives.
Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products; HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS); Fanapt for the treatment of schizophrenia; and PONVORY. Its other products include VHX-896, ASO Molecules, VQW-765, Tradipitant, VTR-297 and VHX-896. The majority of revenue is derived from the Fanapt product sales. Geographically, the company sells its product predominantly in the United States, and also in Israel, Europe, and Canada.